The substrate reduction therapies market is projected to grow from USD 1,844.7 million in 2026 to USD 5,627.9 million by 2036, at a CAGR of 11.8%. Small-molecule SRTs will dominate with a 72.0% market share, while gaucher disease will lead the applications segment with a 46.0% share.